Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849065 | 1.00 | KAT2B (0.41) | KAT2BALDH1A1TSHRMCL1 | |
| SCHEMBL28312340 | 0.89 | KAT2B (0.47) | KAT2BALDH1A1MCL1 | |
| SCHEMBL14911695 | 0.79 | IDO1 (0.45) | KAT2B | |
| SCHEMBL17553821 | 0.79 | KAT2B (0.45) | KAT2BMCL1 | |
| SCHEMBL23293650 | 0.75 | TAAR1 (0.42) | KAT2BTSHRMCL1 | |
| SCHEMBL16016173 | 0.75 | TAAR1 (0.42) | KAT2BALDH1A1TSHR | |
| SCHEMBL15923101 | 0.75 | TAAR1 (0.43) | KAT2BALDH1A1 | |
| SCHEMBL21594374 | 0.75 | HSPA5 (0.48) | KAT2BTSHRMCL1 | |
| SCHEMBL30301878 | 0.75 | TAAR1 (0.42) | KAT2BTSHRMCL1 | |
| SCHEMBL17399958 | 0.75 | KAT2B (0.41) | KAT2BALDH1A1TSHRMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475282-B1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN LA ROCHE (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3475282-B1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN LA ROCHE (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-4108665-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. Hoffmann-La Roche AG (CH) | 2022-12-28 | — | — | EP | disclosed |
| EP-4108665-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. Hoffmann-La Roche AG (CH) | 2022-12-28 | — | — | EP | disclosed |
| CN-115093418-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115073476-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-113943297-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2022-01-18 | — | — | CN | disclosed |
| CN-109311886-B | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-10953369-B2 | Spirocentric compounds and polymers thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3762391-A1 | SPIROCENTRIC COMPOUNDS AND POLYMERS THEREOF | ExxonMobil Research and Engineering Company (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20190127385-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127385-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3475282-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | disclosed |
| EP-3475281-A1 | NOVEL [1,2,31TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | disclosed |
| CN-109348716-A | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives having affinity for cannabinoid type 2 receptors | 豪夫迈·罗氏有限公司 | 2019-02-15 | — | — | CN | disclosed |
| CN-109311886-A | Novel [1,2,3] triazol [4,5-d] pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| WO-2018015088-A1 | NOVEL [1,2,31TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017220517-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127384-A1 | [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES WITH AFFINITY FOR THE TYPE-2 CANNABINOID RECEPTOR | CNR2, CNR1, P2RY2 | KAT2B 4484/4885ALDH1A1 2101/4885TSHR 567/4885 |
| US-10953369-B2 | Spirocentric compounds and polymers thereof | PKD1, PKD2, VIM | KAT2B 3282/4885ALDH1A1 2886/4885TSHR 2361/4885 |
| US-20190127385-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, TBXA2R | KAT2B 3749/4885ALDH1A1 267/4885TSHR 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.